Skip navigation
Watchlist Sponsored By :


Current DateTime: 02:18:32 12 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 02:18:32 12 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 02:18:32 12 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
FDA Calls For Tough Warning on Genentech's Xolair Asthma Drug
Topics:FDA
Sectors:Health Care
Companies:Genentech, Inc.
By: Reuters | 21 Feb 2007 | 12:19 PM ET
Text Size

Genentech's [DNA  Loading...      ()   ] asthma drug Xolair should carry the strongest warning possible about the drug's risk of a serious reaction known as anaphylaxis, U.S. health regulators said Wednesday.

The Food and Drug Administration said anaphylaxis -- a severe allergic reaction -- could occur as late as 24 hours after patients take any amount of the drug, also known as omalizumab. The agency added that doctors and patients should be prepared to treat the reaction, which can cause breathing problems, fainting and hives.

In a statement, the South San Francisco-based biotech said it was still discussing the request for a so-called black box warning with the FDA. "The updated wording and its placement in the label is not yet final," the company said.

Genentech is majority-owned by Swiss drugmaker Roche Holding.

Reports of the reaction to Xolair were seen in clinical trials before the drug was approved in 2003 to treat patients with allergy-related asthma, the FDA said. About one in a thousand patients experienced it.

Continued reports of the problem after that prompted the agency's call for the tough warning given "their life-threatening potential, frequency, and the possibility for the delayed onset of anaphylaxis," the agency added.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
  • They may have wrecked their companies or saved our economy. Tell us what you think.
  • Big pharma embraces social media, but how much should a tightly regulated sector say on Facebook or Twitter?
  • A European dating site finds lovelorn singles from one country to be consistently uglier. Which is it?
  • Contributor David Pogue looks at two of the latest efforts to perfect the digital pocket camera.
  • PepsiCo is ramping up its onsite health facilities for workers.
ADD COMMENTS
Remaining characters


Current DateTime: 01:20:29 12 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 11:27:47 12 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 11:27:47 12 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:00:12 12 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters